TABLE 2.
Exercise effects on inflammatory markers.
| Outcome | Group | Baseline (Mean ± SD) | Postintervention (Mean ± SD) | Baseline to Postintervention | |
|---|---|---|---|---|---|
| Within-Group Difference, Mean (95% CI) | Between-Group Difference, Mean (95% CI) | ||||
| CD40-L | RT-HIIT | 5.86 ± 1.87 | 4.90 ± 1.55 | −1.06 (−1.79 to −0.32)* | 0.19 (−0.60 to 0.99) |
| AT-HIIT | 6.07 ± 1.60 | 5.52 ± 1.18 | −0.48 (−1.30 to 0.35) | 0.74 (−0.05 to 1.53) | |
| UC | 6.52 ± 1.33 | 4.82 ± 1.58 | −1.73 (−2.47 to −0.99)* | Reference | |
| EGF | RT-HIIT | 7.60 ± 1.54 | 6.65 ± 1.35 | −1.06 (−1.76 to −0.36)* | 0.29 (−0.49 to 1.07) |
| AT-HIIT | 7.76 ± 1.50 | 7.14 ± 1.34 | −0.52 (−1.38 to 0.34) | 0.75 (−0.03 to 1.52) | |
| UC | 8.16 ± 1.46 | 6.39 ± 1.53 | −1.77 (−2.55 to −1.00)* | Reference | |
| IL-6 | RT-HIIT | 2.51 ± 0.83 | 2.54 ± 0.74 | −0.01 (−0.39 to 0.37) | −0.47 (−0.87 to −0.07)* |
| AT-HIIT | 2.85 ± 0.96 | 3.03 ± 0.75 | 0.21 (−0.09 to 0.51) | −0.15 (−0.55 to 0.25) | |
| UC | 2.59 ± 1.01 | 3.11 ± 1.01 | 0.49 (0.12 to 0.87)* | Reference | |
| TRAIL | RT-HIIT | 6.98 ± 0.29 | 7.02 ± 0.39 | −0.004 (−0.19 to 0.18) | −0.17 (−0.38 to 0.03) |
| AT-HIIT | 7.18 ± 0.55 | 7.33 ± 0.49 | 0.14 (−0.03 to 0.30) | 0.05 (−0.16 to 0.26) | |
| UC | 7.02 ± 0.51 | 7.21 ± 0.42 | 0.18 (0.03 to 0.33)* | Reference | |
| CD8a | RT-HIIT | 8.19 ± 0.86 | 8.00 ± 0.72 | −0.24 (−0.44 to −0.03)* | −0.28 (−0.57 to 0.004) |
| AT-HIIT | 8.07 ± 0.70 | 7.96 ± 0.74 | −0.12 (−0.29 to 0.06) | −0.20 (−0.48 to 0.09) | |
| UC | 7.99 ± 0.72 | 8.09 ± 0.80 | 0.10 (−0.10 to 0.30) | Reference | |
| DCN | RT-HIIT | 3.55 ± 0.33 | 3.56 ± 0.39 | −0.02 (−0.12 to 0.09) | −0.14 (−0.31 to 0.03) |
| AT-HIIT | 3.64 ± 0.50 | 3.75 ± 0.52 | 0.08 (−0.03 to 0.20) | 0.005 (−0.16 to 0.17) | |
| UC | 3.44 ± 0.54 | 3.62 ± 0.42 | 0.17 (0.03 to 0.30)* | Reference | |
| CCL17 | RT-HIIT | 7.23 ± 1.28 | 6.85 ± 1.23 | −0.45 (−0.94 to 0.03) | 0.15 (−0.44 to 0.74) |
| AT-HIIT | 7.28 ± 0.96 | 7.13 ± 1.08 | −0.12 (−0.62 to 0.38) | 0.40 (−0.19 to 0.99) | |
| UC | 7.56 ± 1.07 | 6.84 ± 1.11 | −0.73 (−1.22 to −0.24)* | Reference | |
| CASP-8 | RT-HIIT | 3.79 ± 1.25 | 3.18 ± 0.91 | −0.75 (−1.34 to −0.16)* | 0.20 (−0.25 to 0.66) |
| AT-HIIT | 3.70 ± 1.13 | 3.43 ± 0.74 | −0.27 (−0.89 to 0.35) | 0.40 (−0.05 to 0.86) | |
| UC | 3.95 ± 1.01 | 3.03 ± 0.86 | −0.96 (−1.39 to −0.53)* | Reference | |
| ICOSLG | RT-HIIT | 3.77 ± 0.42 | 3.79 ± 0.48 | −0.02 (−0.14 to 0.11) | −0.14 (−0.32 to 0.04) |
| AT-HIIT | 3.73 ± 0.55 | 3.84 ± 0.46 | 0.08 (−0.06 to 0.23) | −0.05 (−0.23 to 0.13) | |
| UC | 3.65 ± 0.49 | 3.84 ± 0.43 | 0.18 (0.05 to 0.31)* | Reference | |
| CSF-1 | RT-HIIT | 6.73 ± 0.36 | 6.77 ± 0.41 | −0.01 (−0.16 to 0.13) | −0.13 (−0.30 to 0.03) |
| AT-HIIT | 6.83 ± 0.51 | 6.92 ± 0.45 | 0.08 (−0.04 to 0.20) | −0.03 (−0.19 to 0.13) | |
| UC | 6.68 ± 0.49 | 6.86 ± 0.45 | 0.17 (0.08 to 0.27)* | Reference | |
| IFN-γa | RT-HIIT | 0.88 ± 1.59 | 1.01 ± 1.60 | 0.09 (−0.65 to 0.82) | −0.51 (−1.20 to 0.17) |
| AT-HIIT | 1.20 ± 0.98 | 1.46 ± 0.95 | 0.28 (−0.14 to 0.69) | −0.14 (−0.82 to 0.54) | |
| UC | 0.88 ± 1.65 | 1.49 ± 1.25 | 0.57 (−0.05 to 1.19) | Reference | |
| IL-10a | RT-HIIT | 0.92 ± 0.27 | 0.81 ± 0.26 | −0.08 (−0.28 to 0.13) | 0.13 (−0.02 to 0.29) |
| AT-HIIT | 0.95 ± 0.23 | 0.70 ± 0.18 | −0.29 (−0.40 to −0.19)* | −0.0004 (−0.14 to 0.14) | |
| UC | 0.92 ± 0.26 | 0.71 ± 0.22 | −0.27 (−0.41 to −0.12)* | Reference | |
| FasL | RT-HIIT | 5.18 ± 0.49 | 5.38 ± 0.58 | 0.11 (−0.05 to 0.27) | −0.15 (−0.39 to 0.08) |
| AT-HIIT | 5.06 ± 0.64 | 5.38 ± 0.53 | 0.31 (0.13 to 0.48)* | −0.02 (−0.25 to 0.21) | |
| UC | 5.06 ± 0.60 | 5.42 ± 0.63 | 0.33 (0.16 to 0.51)* | Reference | |
| CXCL9 | RT-HIIT | 6.21 ± 0.73 | 6.73 ± 0.84 | 0.48 (0.13 to 0.83)* | 0.04 (−0.37 to 0.45) |
| AT-HIIT | 6.50 ± 1.03 | 7.13 ± 0.83 | 0.66 (0.32 to 1.00)* | 0.28 (−0.13 to 0.69) | |
| UC | 6.29 ± 0.95 | 6.82 ± 0.94 | 0.47 (0.10 to 0.84)* | Reference | |
| MIC A/B | RT-HIIT | 3.11 ± 1.07 | 3.06 ± 1.04 | −0.06 (−0.19 to 0.06) | −0.14 (−0.30 to 0.03) |
| AT-HIIT | 2.84 ± 1.16 | 2.88 ± 1.16 | 0.02 (−0.09 to 0.14) | −0.06 (−0.22 to 0.11) | |
| UC | 2.97 ± 1.17 | 3.06 ± 1.29 | 0.09 (−0.03 to 0.21) | Reference | |
Baseline values, within-group differences, and between-group differences were based on participants having baseline and postintervention measurements (RT-HIIT = 30, AT-HIIT = 27, UC = 29).
*P < 0.05.
aLog-transformed.
CASP-8, caspase-8; CD40-L, CD40 ligand; CSF-1, macrophage colony stimulating factor 1; CXCL9, C-X-C motif chemokine 9; DCN, decorin; FasL, Fas antigen ligand; ICOSLG, ICOS ligand; MIC A/B, MHC class I polypeptide-related sequence A/B; TRAIL, TNF-related apoptosis-inducing ligand.